ABSTRACT
needed because phenotypic-based assays are labor intensive and not sensitive. Based on the
23
finding that phenotypically confirmed CXCR4-as compared to exclusive CCR5-utilizing strains 24 are less neutralization sensitive, especially to variable loop 1 and 2 (V1-V2) and V3 loop bnAbs,
25
we show that an algorithm that predicts receptor usage identifies envelopes with decreased V3 26 loop bnAb susceptibility. Homology modeling suggests that the primary V3 loop bnAb epitope is 27 equally accessible among CCR5-and CXCR4-using strains although variants that exclusively 28 use CXCR4 have V3 loop protrusions that interfere with CCR5 receptor interactions. On the 29 other hand, homology modeling also shows that envelope V1 loop orientation interferes with V3 30 loop directed bnAb binding, and this accounts for decreased neutralization sensitivity in some 31 but not all cases. Thus, there are likely different structural reasons for the co-receptor usage 32 restriction and the differential bnAb susceptibility. Algorithms that use sequence data to predict 33 receptor usage and antibody-envelope homology models can be used to identify variants with 34 decreased sensitivity to V3 loop and potentially other bnAbs.
35

INTRODUCTION
51
Multiple broadly neutralizing antibodies (bnAbs) are being examined as novel 52 therapeutics against human immunodeficiency virus type 1 (HIV-1) infection [1] [2] [3] [4] [5] [6] . In contrast to 53 the current highly effective antiretroviral drugs (ARVs), antibody-based therapies require less 54 frequent dosing, can be effective against drug resistant variants, and may potentiate host 55 humoral responses [7] . Prior to initiating ARVs, HIV-1 infected patients are routinely evaluated 56 for the presence of drug resistant strains, primarily using sequence-based methods [8] .
57
Sequence-based methods are also needed to identify pre-treatment variants with reduced bnAb 58 susceptibility because phenotypic-based assays are cumbersome and lack sensitivity [1, 4] .
59
BnAbs attach to diverse envelope (Env) domains, such as the apex, high mannose 60 patch, CD4 binding site (bs), surface unit (gp120) -transmembrane (gp41) interface, and gp41 61 membrane proximal external region (MPER) [9] . The apex is targeted by variable loop 1 and 2
(V1-V2) directed bnAbs that bind the asparagine (N)-linked glycan at Env position 160 (N160)
63
[10]. Anti-variable loop 3 (V3 loop) bnAbs attach to an N-linked glycan at Env position 332 in the 64 high mannose patch [11] . While the activity of these bnAbs primarily depends on the presence 65 of these glycans, other amino acids, especially those in and around the V1-V2 and V3 Env 66 regions, also impact neutralization [12, 13] . In addition to being antibody targets, the V1-V2 and 67 V3 loops also influence binding to either the CCR5 or CXCR4 co-receptor, and this attachment 68 is necessary for host cell entry [14] [15] [16] . This overlap provides the scientific basis for speculating 69 that there is an association between the receptor a virus utilizes to enter cells and its bnAb Table 1) . A primary R5 Env group was also generated by randomly selecting 1 phenotypically 170 confirmed CCR5 only using strain from 11 different individuals (Table S3) .
171
Neutralization susceptibility was compared between the group of primary X4 and R5
172
Envs to a standard comparator generated by pooling plasma from ten HIV-1B infected 173 individuals, different from the seventeen subjects above. We chose to compare the groups (Fig 2F and 2G) . The primary X4 viruses 184 were around 2 fold less sensitive to V1-V2 antibodies, PG9 and PG16, but these differences 185 were also not statistically significant ( Fig. 2H and 2I ). In contrast, the R5 as compared to the X4 186 variants had comparable sensitivity to CD4bs and MPER bnAbs (Fig 2J and 2K) (Fig 3A -3E ). This protuberance 212 coincided with the location of the insertion either at the tip or the base of the V3 loop (Fig. S2 ).
213
The 1924 X4 V3 loop also contained a protrusion in the V3 loop in the absence of an insertion
(Fig. 3E). The protuberance directly corresponded to the observed aspartic acid (D) to lysine (K)
215 substitution at position 25 of the V3 loop compared to the R5 variant.
216
To understand the impact of these protrusions on co-receptor usage, the predicted V3 Table 2 ).
250
Thus, the V3 loop insertion related protrusion hinders CCR5 binding, but it does not appear to 251 limit access to the V3 loop bnAb epitope.
252
Contact between the V1 loop and the bnAb impacts susceptibility.
253
The homology models also revealed that the V1 loop of the highly sensitive Envs, pointed away 254 from the PGT121 precursor and the 10-1074 bnAb (Fig. 4) (Fig 4) , the relatively resistant X4
277
(4102-3_6 and 4102-3_5) Envs had greater CSA as compared to the highly sensitive R5 (4102-278 61 and 4102-2_17) R5 Envs (Table 2) . Among the original and chimeric Envs, the estimated 279 CSA increased as neutralization PGT121 and 10-1074 AUC decreased ( Fig. 5A and 5B). Thus,
280
Envs predicted to have greater V1 loop proximity to the antibody are more neutralization 281 resistant. To further confirm this association, 3H+109L and 10-1074 CSA was estimated for all
282
Envs in the CATNAP database with a predicted N332 site. There was a statistically significant 283 association between estimated CSA and bnAb sensitivity among Envs that had a detectable IC 50
284
( Fig. 5C and 5D ). As CSA increased, sensitivity to PGT121 and 10-1074 decreased. In 285 aggregate, this suggests that CSA can be used to estimate V1 loop clash with an antibody, and 286 V1 loop interference impacts neutralization susceptibility to V3 loop bnAb. 
297
This highly accurate algorithm yields a probability that an input V3 Env sequence is X4. (Fig. 5F ).
307
For both PGT121 and 10-1074, 175 CATNAP Envs were randomly selected as a training 308 set to determine a CRUSH cut-off that would achieve a minimum 90% specificity for predicting 309 an IC 50 greater than 2 ug/ml. The remaining 163 and 114 Envs were used as a test set for 310 PGT121 and 10-1074 respectively. In both cases, a CRUSH value more than 0.16 yielded 311 greater than 90% specificity for the test set. This CRUSH cut-off had 93.0% (95% CI 89 -96%) 312 and 91% (95% CI 87 -94%) specificity for PGT121 and 10-1074 respectively against the entire 313 CATNAP data set. The positive predictive value (PPV) was 65% for PGT121 but only 33% for 314 10-1074 ( Fig. 5G and 5H ). This difference likely occurred because there were smaller number of 315 CATNAP Envs with a CRUSH value greater than 0.16 with available IC 50 data against 10-1074 316 (n = 33) as compared to PGT121 (n = 48), and PPV as opposed to specificity is dependent on 317 sample composition. In both cases, however, the proportion of N332 positive Env variants with a 318 CRUSH score greater than 0.16 had between 2 to 3 fold greater likelihood of having an V3 loop bnAb IC 50 more than 2 ug/ml as compared to strains with predicted glycosylation at the 332 320 amino acid position but less than 16% probability of being X4 ( Fig. 5G and 5H ). Similar analysis 321 was not conducted for CSA because it demonstrated poor test characteristics against the entire 322 data set. In aggregate, Envs both containing the predicted primary V3 loop bnAb epitope (N332) 323 and estimated to have greater than 16% probability of being an X4 variant had a relatively high 324 likelihood of being relatively insensitive to PGT121 and 10-1074.
Discussion
326
Passive administration of a V3 loop bnAb (10-1074) decreases plasma viremia and 327 delays virus re-emergence in some but not all treated individuals [1, 3, 4] . In these trials, pre-328 infusion virus susceptibility impacted subsequent treatment efficacy regardless of whether 10-329 1074 was used as monotherapy or in combination with another bnAb. These results provide the 330 impetus to develop techniques to screen pre-existing variants for bnAb neutralization sensitivity.
331
In this study, we used the observation that phenotypically-confirmed CXCR4-using as compared 332 to R5 variants are less neutralization susceptible to heterologous plasma and to V1-V2 and V3 333 directed bnAbs to develop such a screening test. As an application of these results, we showed 334 that an algorithm that uses sequences to predict receptor usage identifies variants with 335 decreased susceptibility to V3 loop bnAbs. We also developed sequence-input homology protrusions present in X4 variants, however, do not directly limit access to the epitopes 383 important for V3 loop directed bnAb activity. Thus, the structural basis for the inability to use the 384 CCR5 receptor does not account for decreased sensitivity to V3 loop bnAbs. Our observation 385 that exchanging V1-V2 loops among Envs did not change co-receptor usage but it did impact 386 sensitivity to V3 loop bnAbs further supports this notion.
387
The sequential co-receptor evolution from R5 to R5X4 and then X4 requires multiple 388 sequence modifications within and outside the V3 loop [50] . We observed that Env variants with 389 merely greater than 16% probability of being X4 had a high likelihood of having a V3 loop bnAb 390 IC 50 greater than 2 ug/ml. Majority of Env strains with around 16% X4 probability likely use the 391 CCR5 and not the CXCR4 receptor to enter cells. These Env variants, however, likely contain 392 some sequence modifications that are commonly observed among CXCR4-using strains. As 393 opposed to only the specific V3 loop differences among R5 versus X4 strains, it is likely that the multitude of changes that occur as an Env transitions from exclusive CCR5 to only CXCR4 395 usage contribute to decreasing sensitivity to V3 loop bnAbs.
396
The V3 loop sequence changes that lead to the predicted protrusions are similar to those 
410
In general, plasma samples displayed a decreased ability to neutralize Envs in the CXCR4- Supplementary Table 1 . Samples with R5 only and dual-mixed virus population.
Supplementary Table 2 . Envelopes in the CXCR4-using Env panel.
Supplementary Table 3 . Variants in the primary X4 and R5 Env panel.
Supplementary Table 4 . Templates for homology modeling for X4 and R5 V3 loops.
